Patient-Reported Outcomes in Psoriatic Arthritis

Overview

Journal Rheum Dis Clin North Am

Publisher Elsevier

Specialty Rheumatology

Date 2016 May 3

PMID 27133489

Citations 31

Authors

Ana-Maria Orbai

Alexis Ogdie

Affiliations

Soon will be listed here.

Abstract

Patient-reported outcome (PRO) measures are an important component to assessing disease impact and therapy response in patients with psoriatic arthritis (PsA). Overall, there are few PsA-specific PROs. Most PROs used in PsA are borrowed from other diseases (eg, rheumatoid arthritis and ankylosing spondylitis) or general population PROs. PROs are used in PsA clinical trials and in the clinical management of PsA. In this review, we discuss the most commonly used PRO in PsA, including their inclusion in composite measures. Future studies may be helpful to determine the best performing PROs in patients with PsA.

Citing Articles

Tumor necrosis factor (TNF) inhibitors for psoriatic arthritis.

Cagnotto G, Bruschettini M, Strozyk A, Scire C, Compagno M Cochrane Database Syst Rev. 2025; 2:CD013614.

PMID: 39945386 PMC: 11822884. DOI: 10.1002/14651858.CD013614.pub2.

The impact of psoriatic arthritis on quality of life: a systematic review.

James L, Hailey L, Suribhatla R, McGagh D, Amarnani R, Bundy C Ther Adv Musculoskelet Dis. 2024; 16:1759720X241295920.

PMID: 39717741 PMC: 11664531. DOI: 10.1177/1759720X241295920.

Patient-Reported and Economic Racial and Ethnic Disparities in Patients with Psoriatic Arthritis: Results from the National Health and Wellness Survey.

Lin I, Krupsky K, Way N, Patel A, Tieng A Rheumatol Ther. 2024; 11(6):1569-1590.

PMID: 39343841 PMC: 11557857. DOI: 10.1007/s40744-024-00717-7.

Development of a questionnaire to assess the patient perspective regarding challenges in psoriatic arthritis treatment-a mixed-methods study.

Lucas Ribeiro A, Tessari J, Lubianca Kohem C, Esther Palominos P, Mendonca da Silva Chakr R Adv Rheumatol. 2024; 64(1):72.

PMID: 39300553 DOI: 10.1186/s42358-024-00414-7.

Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled Trials.

Kavanaugh A, Mease P, Gossec L, Ranza R, Tsuji S, Douglas K ACR Open Rheumatol. 2024; 6(11):736-745.

PMID: 39087872 PMC: 11557994. DOI: 10.1002/acr2.11714.

References

Pincus T, Furer V, Keystone E, Yazici Y, Bergman M, Luijtens K . RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural.... Arthritis Care Res (Hoboken). 2011; 63(8):1142-9. DOI: 10.1002/acr.20481. View

Coates L, FitzGerald O, Mease P, Gladman D, Strand V, Goel N . Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11. J Rheumatol. 2014; 41(4):782-91. DOI: 10.3899/jrheum.131250. View

Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J . Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005; 32(5):811-9. View

Guyatt G, Feeny D, Patrick D . Measuring health-related quality of life. Ann Intern Med. 1993; 118(8):622-9. DOI: 10.7326/0003-4819-118-8-199304150-00009. View

Cauli A, Gladman D, Mathieu A, Olivieri I, Porru G, Tak P . Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol. 2011; 38(5):898-903. DOI: 10.3899/jrheum.100857. View

Billing E, McKenna S, Staun M, Lindqvist U . Adaptation of the Psoriatic Arthritis Quality of Life (PsAQoL) instrument for Sweden. Scand J Rheumatol. 2010; 39(3):223-8. DOI: 10.3109/03009740903347975. View

Finlay A, Khan G . Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3):210-6. DOI: 10.1111/j.1365-2230.1994.tb01167.x. View

Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman D . Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients. Arthritis Care Res (Hoboken). 2014; 67(2):264-72. DOI: 10.1002/acr.22401. View

Kwok T, Pope J . Minimally important difference for patient-reported outcomes in psoriatic arthritis: Health Assessment Questionnaire and pain, fatigue, and global visual analog scales. J Rheumatol. 2010; 37(5):1024-8. DOI: 10.3899/jrheum.090832. View

10.

Osterhaus J, Purcaru O, Richard L . Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA). Arthritis Res Ther. 2009; 11(3):R73. PMC: 2714119. DOI: 10.1186/ar2702. View

11.

Calin A, Garrett S, Whitelock H, Kennedy L, OHea J, Mallorie P . A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994; 21(12):2281-5. View

12.

Husted J, Cook R, Farewell V, Gladman D . Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol. 2000; 53(5):459-68. DOI: 10.1016/s0895-4356(99)00206-1. View

13.

Martin M, McCarrier K, Chiou C, Gordon K, Kimball A, Van Voorhees A . Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity. J Dermatolog Treat. 2012; 24(4):255-60. DOI: 10.3109/09546634.2012.759639. View

14.

Husted J, Gladman D, Long J, Farewell V . Relationship of the Arthritis Impact Measurement Scales to changes in articular status and functional performance in patients with psoriatic arthritis. J Rheumatol. 1996; 23(11):1932-7. View

15.

Prevoo M, van t Hof M, Kuper H, van Leeuwen M, van de Putte L, van Riel P . Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38(1):44-8. DOI: 10.1002/art.1780380107. View

16.

Mease P, Woolley J, Bitman B, Wang B, Globe D, Singh A . Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol. 2011; 38(11):2461-5. DOI: 10.3899/jrheum.110546. View

17.

Mattei P, Corey K, Kimball A . Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2013; 28(3):333-7. DOI: 10.1111/jdv.12106. View

18.

Ward M, Guthrie L, Alba M . Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials. Ann Rheum Dis. 2014; 74(9):1691-6. PMC: 4216638. DOI: 10.1136/annrheumdis-2013-205079. View

19.

Helliwell P, Kavanaugh A . Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab. Arthritis Care Res (Hoboken). 2013; 66(5):749-56. DOI: 10.1002/acr.22204. View

20.

Osterhaus J, Purcaru O . Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity in patients with psoriatic arthritis. Arthritis Res Ther. 2014; 16(4):R140. PMC: 4226958. DOI: 10.1186/ar4602. View